What Is a 510(k)? FDA Clearance Timelines, Costs, and Pitfalls Explained
2026-09-14 · Caduvo Team
A clear-eyed look at the 510(k) premarket notification pathway: substantial equivalence, submission contents, realistic timelines, user fees, and the most common reasons the FDA sends an Additional Information request.
You’ve got a working prototype, benchtop data, and a design freeze date circled on the calendar. The next step: answer what is a 510k and figure out whether your device needs one. The 510(k) pathway is the most common FDA market entry route for medical devices, but too many teams treat it as a paperwork exercise and lose months to avoidable holds. This guide lays out the mechanics—substantial equivalence, submission contents, realistic timelines, user fees, and where submissions typically stall—so you can plan a clearance strategy that runs on facts, not hope.
What Is a 510(k)? Substantial Equivalence in Practice
A 510(k) is a premarket notification submitted to FDA under section 510(k) of the Food, Drug, and Cosmetic Act. Its purpose is to demonstrate that a new device is substantially equivalent to a legally marketed predicate device—one that either was on the market before May 28, 1976, or has itself been cleared through the 510(k) process.
Substantial equivalence does not mean the devices are identical. It means the new device has the same intended use and the same technological characteristics as the predicate, or any differences in technology do not raise new questions of safety and effectiveness. FDA makes a comparative determination, not a standalone safety finding. That’s why the predicate device is the single most important choice in any 510(k) submission. A well-chosen predicate shortens review; a weak one leads straight to a hold letter. For a step-by-step method on selecting and documenting a predicate, see predicate device selection guide.
The outcome is 510(k) clearance, not approval. We’ll return to that distinction shortly.
Who Needs 510(k) Clearance?
Most Class II devices require a 510(k) unless they are explicitly exempt under 21 CFR. Some Class I devices and a small number of unclassified devices also need one. The starting point is to identify your device’s classification regulation and FDA product code. If the product code lists a 510(k) requirement and no exemption, you must submit. If your device is novel and falls into a class that normally requires a 510(k) but you believe it is low-to-moderate risk, you might instead consider the De Novo pathway to get classified without a predicate. A quick reference on class determinations and product codes is in FDA medical device classification.
Practically speaking, if you are developing a device that fits within an existing Class II category—such as a surgical instrument, patient monitor, or diagnostic catheter—and you have a clear predicate, plan on a 510(k).
What Goes Into a 510(k) Submission?
A complete 510(k) submission today is an electronic copy (eCopy) that follows FDA’s Refuse to Accept (RTA) checklist. The core sections:
- Cover letter and administrative forms (Form 3514, Truthful and Accurate Statement, Indications for Use form)
- Device description including part numbers, materials, and full intended use
- Predicate comparison table that maps every feature of your device to the predicate, highlighting any differences and how you addressed them
- Performance testing summary —bench testing, biocompatibility (ISO 10993), electrical safety (IEC 60601), electromagnetic compatibility, and software documentation (IEC 62304) if applicable
- Sterilization and shelf-life data when the device is supplied sterile or has a shelf life
- Labeling —instructions for use, package labels, operator manuals
- Manufacturing and quality controls, including compliance with the Quality System Regulation (21 CFR Part 820)
Every 510k submission must stand on these sections. Omissions, especially around testing, are the top reason FDA issues an Additional Information (AI) request. Think of the RTA checklist as your preflight check: if the submission fails administrative review, it is returned without a substantive review.
Timelines, Fees, and Why You’ll Probably Get an AI Letter
The FDA’s statutory goal under MDUFA V for a traditional 510(k) is 90 days from submission to a final decision. In practice, the clock rarely runs straight through.
- Days 1–60: Administrative review. FDA checks for completeness against the RTA checklist. If accepted, the submission moves to substantive review. If refused, you get 180 days to correct and resubmit.
- Days 60–150: Substantive review. The reviewer examines performance data, predicate comparison, and labeling. In nearly every case, questions arise.
- AI Hold: FDA sends an Additional Information letter, formally stopping the review clock. You respond with the requested data. FDA then has 180 days to review the response and issue a decision.
Real-world timing from initial submission to final clearance letter often runs 6 to 12 months, depending on how many AI rounds occur and how quickly your team can turn around test reports.
Costs: For FY2024, the standard 510(k) user fee is $19,870. Small businesses (under $100 million in revenue) pay $4,967. But the fee is just the entry ticket. Testing—battery of safety, EMC, biocompatibility, and sometimes clinical performance data—can push the total spend to $50,000–$150,000 or more for a first-time submission.
Where submissions typically stall:
- Predicate comparison fails to address a technological difference with data
- Sterilization validation is missing or uses generic rationales
- Electromagnetic compatibility testing was skipped or incomplete
- Labeling includes indications or claims beyond those cleared for the predicate
- Software documentation lacks a complete hazard analysis
Cleared, Not Approved: Why Words Matter
A 510(k) results in clearance, not approval. Approval is reserved for PMAs, HDEs, and certain other pathways where FDA makes an affirmative determination of safety and effectiveness based on clinical data. When FDA clears a 510(k), it is saying the device is substantially equivalent to a predicate; it is not endorsing the device’s safety and effectiveness from scratch.
This distinction has real consequences. Marketing materials cannot say “FDA approved.” Legal liability theories that rely on FDA approval as a shield fall flat when the device was only cleared. And if your device later requires a PMA due to higher risk, the regulatory bar changes dramatically. For a comparison of clearance and approval pathways, see 510(k) vs PMA vs De Novo.
Actionable Takeaways
- Start with the predicate. Spend as much time on predicate selection and the comparison table as you do on testing. A weak predicate delays everything.
- Run your own RTA review. Before submitting, go through FDA’s RTA checklist line by line. Don’t let a formatting error or missing form buy you 60 extra days.
- Budget for the AI cycle. Assume you will receive at least one Additional Information request and that it will add 3–6 months to the timeline.
- Lock down labeling early. Indications for use and claims must hew closely to the predicate. Overbroad labeling is a frequent AI trigger.
- Remember the difference between cleared and approved. Use the right language internally and externally—it shapes expectations with investors, partners, and clinicians.